
Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.
Research Presented at CHEST 2024 reported on how mepolizumab can improve asthma control, and reduce exacerbations of concurrent asthma and COPD.
Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.
In an installment of Drug Topics’ 5 Questions With a Pharmacist, Anthony Minniti of Bell Pharmacy in Camden, New Jersey, discussed pharmacy in his community and the challenges that come with it.
Drug Topics sat down with Benjamin Jolley, PharmD, of Jolley’s Compounding Pharmacy, to discuss the pharmacy industry and his experience in a myriad of roles within the profession.
Adherence interventions and comprehensive reviews can reduce health care costs, boost revenue, and improve patient outcomes.
The Healgen Rapid Check COVID-19/Flu A&B Antigen Test is the first at-home test to be granted marketing authorization using a traditional premarket review pathway.
The 70-plus-page lawsuit is directed at Express Scripts for its dealings with drug manufacturers in fueling the US opioid crisis.
Florida-based pharmacist Brad Phillips, PharmD, BCACP, speaks to the importance of pre-planning, emergency refills, medication storage, and post-storm safety measures to ensure medication security during hurricanes.
Medication therapy management can change the trajectory of patient health outcomes. Here is how pharmacists can ensure adherence and compensation.
Research presented at CHEST 2024 examined the effect of steroid choice on individuals who have a dual diagnosis of heart failure and COPD.
Research presented at CHEST 2024 outlined the heart failure risks associated with COVID-19 infection and emphasized the importance of vaccination to prevent adverse outcomes.
A roundtable session discussed the real-world implications of applying DIR fees at the point of sale rather than through retroactive clawback.
See what’s trending in pharmacy with a preview of the Total Pharmacy October issue.
The company will be presenting the full BATURA study data as a late-breaker oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
Whether patients present with complaints of an aching muscle from a workout or a sudden twinge in the back, consider recommending these topical analgesics.
Although there has recently been an effort to improve pediatric pain treatment, it is still often underestimated and not adequately managed.
In case you missed it, this week we had stories about the availability of the first liquid nonstimulant for ADHD, pharmacy technicians as "vaccine champions," SGLT2i's heart-healthy benefits, and more.
Check out this recap of articles published on our sister sites during the past week.
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
Cologuard Plus is approved for adults aged 45 years and older who are at average risk for the disease.
Social pressures, physiological changes, mental health challenges, and burnout all complicate diabetes management among adolescents.
Researchers aimed to determine whether or not opioids were appropriate for treating adolescents experiencing chronic pain.
Check out important updates from the FDA for the week of September 30.
Researchers suggest that vaccine champion programs could be a promising avenue to increasing immunization rates.
Many public health officials aren’t surprised by the decline in vaccine coverage, although its underlying causes present unique challenges.
Senators Ron Wyden and Sherrod Brown wrote a letter to the Federal Trade Commission calling to explore yet another PBM tactic impeding competition.
See what’s trending in pharmacy with a preview of the Drug Topics September/October issue.
This year’s meeting will take place from October 6 to 9 in Boston, Massachusetts.
The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.